MaRS Future of Medicine Series - Personalized Cancer Treatment
Tuesday, February 14, 2012 from 12:00 PM to 1:30 PM (EST)
John Connolly is Managing Director of York Medtech Partners, a medtech incubator based in Toronto, and a Founder and VP Corporate Development of Rna Diagnostics Inc. John has spent 15 years as a venture investor and startup entrepreneur in the Canadian medtech industry.
John will describe the founding of Rna Diagnostics, its success to date and the challenges it faces as it brings its game-changing RNA Disruption Assay™ technology to market.
Rna Diagnostics Inc. has developed a real-time cancer chemotherapy guidance tool. Less than 25% of breast cancer chemotherapy patients derive survival benefit from chemotherapy. All patients endure toxic effects. Reduction of unnecessary chemotherapy is a top priority for breast cancer specialists. The RNA Disruption Assay (RDA™) is the only diagnostic tool that measures, early in treatment, how a patient is responding to chemotherapy. Administered during the first three cycles, RDA™ measures chemotherapy effectiveness. Effective therapy is confirmed for responding patients, while non-responders may be switched from chemotherapy to alternate therapies, thereby sparing them toxic side effects. RDA™ improves patient outcomes while lowering breast cancer treatment costs.
MaRS Future of Medicine™ Series is a must-attend event for anyone engaged in translational research or commercial development within the life sciences.
Part of the MaRS Future of Medicine™ Series
About the Speaker
John Connolly is Managing Director of York Medtech Partners, a medtech incubator based in Toronto, and a Founder and VP Corporate Development of Rna Diagnostics Inc. John has spent 15 years as a venture investor and startup entrepreneur in the Canadian medtech industry.ttawa.
When & Where
MaRS Discovery District, Social Innovation Generation & Ashoka Canada present
MaRS (www.marsdd.com) is a large scale, mission driven innovation centre located in Toronto and networked across Ontario, focused on building Canada’s next generation of technology companies.
MaRS works closely with entrepreneurs to grow and scale their ventures into global market leaders in life sciences and health care, information, communications and entertainment technologies, cleantech, advanced materials and engineering, as well as innovative social purpose businesses.
Social Innovation Generation (SiG) (www.sigeneration.ca) is a collaborative partnership founded by The J.W. McConnell Family Foundation, the University of Waterloo, the MaRS Discovery District, and the PLAN Institute. Our ultimate goal is to support whole system change through changing the broader economic, cultural and policy context in Canada to allow social innovations to flourish.
Ashoka (canada.ashoka.org) is the global association of the world’s leading social entrepreneurs – individuals with system-changing solutions for the world’s most urgent social problems. Ashoka is redefining the global citizen sector by creating a system of collaborative entrepreneurship. Connecting the work of individual social entrepreneurs to business, academic and public sector partners, they create a network effect driving the sector forward and developing new solutions to global problems.